PolyPid Ltd.
Business
PolyPid Ltd. is an innovative biopharmaceutical company developing long-acting, controlled‑release medicines that deliver therapy locally at the site of care. Its main product candidate is D‑PLEX100, which pairs the proprietary PLEX technology with doxycycline for localized prevention of surgical site infections, and its pipeline includes OncoPLEX (intra‑tumoral docetaxel) and a long‑acting GLP‑1 delivery platform. The company operates clinical development, in‑house cGMP manufacturing, and R&D/licensing activities centered on the PLEX/Kynatrix platforms. It pursues regulatory approvals in the United States and Europe and plans commercialization through partnerships, hospital channels and regional licensees such as Advanz in the EEA and UK.
Summary from filing dated 2026-02-25
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-34.17M |
| Total assets | $22.31M |
| Total liabilities | — |
| Stockholders' equity | $10.97M |
| Operating cash flow | $-27.88M |